Evidence map›Paper›PMID 39412595›Full record

ArticleProbiotics and antimicrobial proteins2025

Characterization of a Peptidoglycan-Degrading Protein: Biochemical and Antimicrobial Characteristics, Antibiotic Synergism, and Delivery System Innovation.

Viviane C Oliveira, Nathália G Rosa-Garzon, Amanda C S D Rocha, Rachel M Monteiro, Yasmim G Gonçalves, Marcelo Kravicz, Maria A Juliano, Luiz Juliano, Priscyla D Marcato, Claudia H Silva-Lovato and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Probiotics and antimicrobial proteins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Viviane C Oliveira *Department of Dental Materials and Prosthodontics, Ribeirão Preto School of Dentistry, University of São Paulo, Ribeirão Preto, SP, Brazil.
Nathália G Rosa-Garzon *Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. Prof. Dr. Zeferino Vaz, SN. Campus Universitário, Monte Alegre, Ribeirão Preto, SP, Brazil. nathaliagrosa@usp.br.
Amanda C S D RochaHuman Exposome and Infectious Diseases Network (HEID), Ribeirão Preto College of Nursing, University of São Paulo, Ribeirão Preto, SP, Brazil.
Rachel M MonteiroHuman Exposome and Infectious Diseases Network (HEID), Ribeirão Preto College of Nursing, University of São Paulo, Ribeirão Preto, SP, Brazil.
Yasmim G GonçalvesDepartment of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. Prof. Dr. Zeferino Vaz, SN. Campus Universitário, Monte Alegre, Ribeirão Preto, SP, Brazil.
Marcelo KraviczDepartment of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. Prof. Dr. Zeferino Vaz, SN. Campus Universitário, Monte Alegre, Ribeirão Preto, SP, Brazil.
Maria A JulianoDepartment of Biophysics, Paulista School of Medicine, Federal University of São Paulo, São Paulo, SP, Brazil.
Luiz JulianoDepartment of Biophysics, Paulista School of Medicine, Federal University of São Paulo, São Paulo, SP, Brazil.
Priscyla D MarcatoDepartment of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. Prof. Dr. Zeferino Vaz, SN. Campus Universitário, Monte Alegre, Ribeirão Preto, SP, Brazil.
Claudia H Silva-LovatoDepartment of Dental Materials and Prosthodontics, Ribeirão Preto School of Dentistry, University of São Paulo, Ribeirão Preto, SP, Brazil.
Hamilton CabralDepartment of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. Prof. Dr. Zeferino Vaz, SN. Campus Universitário, Monte Alegre, Ribeirão Preto, SP, Brazil.
Evandro WatanabeDepartment of Restorative Dentistry, Ribeirão Preto School of Dentistry, University of São Paulo, Ribeirão Preto, SP, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global health threat posed by antibiotic resistance has led to new research involving bacteriophage-encoded enzymes. This study characterized a new peptidoglycan-degrading protein and evaluated its synergism with colistin and its antimicrobial efficacy when conjugated with polycationic-polymer nanoparticles. The gene that codes for endolysin in the vB_PaeM_USP2, a Pseudomonas aeruginosa bacteriophage, was cloned and expressed in Escherichia coli. The recombinant endolysin (rEnd2) was purified and its biochemical properties were determined using peptidoglycan substrate. The enzymatic activity was measured through peptidoglycan layer degradation and a decrease in turbidity of permeabilized Gram-negative bacteria. The antimicrobial activity of rEnd2, alone and in combination with colistin, was evaluated by checkerboard assay. The antibacterial activity of the cationic lipid oleylamine (OAM) conjugated with rEnd2 (OAM-rEnd2) was evaluated by time killing assay. The rEnd2 is structurally analogue with other endolysins and showed muramidase activity. The rEnd2 maintained higher activity between pH 6.0 to 7.5, had maximum activity at 35 °C, and was not affected by chaotropic and reducing reagents. It was sensitive to an increase in surfactant concentration, being inactivated by sodium dodecyl sulfate and cetyltrimethylammonium bromide. Ions exhibited neither a positive nor a negative effect on enzyme activity. The rEnd2 showed clear muralytic activity and decreased turbidity of permeabilized Gram-negative bacteria. However, it did not control bacterial growth despite the combination with an antibiotic and its complexation with polycation (OAM-rEnd2 nanoparticle conjugate). The rEnd2 did not show clear antimicrobial activity suggesting further optimization of conditions for its activity or engineering and modification.

Indexed as

Anti-Bacterial AgentsEndopeptidasesPeptidoglycanViral ProteinsBacteriophagesDrug Delivery SystemsDrug SynergismEscherichia coliMicrobial Sensitivity TestsNanoparticlesPseudomonas aeruginosaRecombinant ProteinsAnti-Bacterial AgentsendolysinEndopeptidasesPeptidoglycanRecombinant ProteinsViral ProteinsAntimicrobial activityBacteriophageColistinEndolysinPolycation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.